Ralph M. Wasch

Hugstetter Str. 55
Freiburg, BW 79106, Germany

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 183 publications

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

DECIDER-2: Prospective randomized multicenter phase III trial of decitabine and venetoclax administered in combination with all-trans retinoic acid or placebo in patients with acute myeloid leukemia who are ineligible for induction chemotherapy.

Journal: BMC cancer

Published: June 16, 2026

Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.

Pre-CAR-T B-cell-directed immunotherapy exposure and outcomes after CD19 CAR-T for large B-cell lymphoma: An EBMT registry analysis.

Journal: Bone marrow transplantation

Published: May 20, 2026

Peri-transplant ruxolitinib prophylaxis improves outcome in patients receiving allogeneic hematopoietic cell transplantation for myelofibrosis.

Peri-transplant ruxolitinib prophylaxis improves outcome in patients receiving allogeneic hematopoietic cell transplantation for myelofibrosis.

Journal: Transplantation and cellular therapy

Published: May 08, 2026

Peri-Transplant Ruxolitinib Prophylaxis Improves Outcome in Patients Receiving Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis.

Peri-Transplant Ruxolitinib Prophylaxis Improves Outcome in Patients Receiving Allogeneic Hematopoietic Cell Transplantation for Myelofibrosis.

Journal: Transplantation and cellular therapy

Published: May 08, 2026

Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.

Characterisation of TP53 mutational features and outcomes of acute myeloid leukaemia after allogeneic haematopoietic cell transplantation.

Journal: Bone marrow transplantation

Published: April 27, 2026

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Teclistamab and Daratumumab Immune-Based Doublet Therapy for Relapsed/Refractory Multiple Myeloma: the TRIMM-2 Study.

Journal: Blood advances

Published: April 03, 2026

Performance evaluation of a CD34 expression assay by digital PCR in bone marrow harvest from healthy donors.

Performance evaluation of a CD34 expression assay by digital PCR in bone marrow harvest from healthy donors.

Journal: Transfusion

Published: March 17, 2026

Risk factors and clinical impact of bone pain in patients with multiple myeloma - A prospective interdisciplinary study.

Risk factors and clinical impact of bone pain in patients with multiple myeloma - A prospective interdisciplinary study.

Journal: Journal of bone oncology

Published: March 10, 2026

Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Ten-day decitabine vs "3+7" in patients with AML aged ≥60 years: long-term results of the randomized phase 3 EORTC trial AML21.

Journal: Blood neoplasia

Published: February 20, 2026

Inpatient Rehabilitation Improves Physical and Mental Health in Multiple Myeloma: A Prospective Cohort Study.

Inpatient Rehabilitation Improves Physical and Mental Health in Multiple Myeloma: A Prospective Cohort Study.

Journal: Cancers

Published: January 12, 2026

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.

Donor lymphocyte infusions for recurrence of myeloid neoplasms after allogeneic hematopoietic cell transplantation in the era of hypomethylating agents and BCL2 inhibitors.

Journal: Annals of hematology

Published: December 13, 2025

Machine learning-based prediction of one-year mortality after alloHCT identifies the impact of pre-transplant immunity and inflammation.

Machine learning-based prediction of one-year mortality after alloHCT identifies the impact of pre-transplant immunity and inflammation.

Journal: Frontiers in immunology

Published: November 13, 2025

Showing 1-12 of 183

Last Updated: 09/26/2026